Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) As a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

NCT04553692 is registered in ClinicalTrials.gov with IGM Biosciences, Inc. as lead sponsor.

NCT NCT04553692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04553692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) As a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Lead sponsor
IGM Biosciences, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 23, 2020
Completion date
January 20, 2025
Enrollment
272 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chondrosarcoma, chronic lymphocytic leukemia, colorectal cancer, non hodgkin lymphoma, sarcoma, small lymphocytic lymphoma, solid tumor